Alkhafaji, S., Magbanua, M. J. M., Veer, L. V. T., Giridhar, K., Goetz, M. P., Mukhtar, R., Vaklavas, C., Elias, A. D., Wei, M., Hirst, G. L., Rugo, H. S., Huppert, L. A., Symmans, W. F. F., Borowsky, A. D., Swigart, L. B., Onishi, N., Yee, D., Hylton, N., Esserman, L., Chien, J. (2025). Circulating tumor DNA (ctDNA) in patients with stage 2/3 HR+HER2-negative breast cancer (BC) treated with neoadjuvant endocrine therapy (NET) in the I-SPY2 endocrine optimization pilot (EOP) trial.. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2025.43.16_suppl.3008